{"id":"multiple-product-prep-program","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Renal function changes"},{"rate":null,"effect":"Bone density loss"}]},"_chembl":{"chemblId":"CHEMBL4297812","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The Multiple Product PrEP Program offers various FDA-approved PrEP medications (primarily tenofovir/emtricitabine-based regimens) through the University of Alabama at Birmingham to increase access and adherence to HIV prevention. These antiretrovirals work by inhibiting reverse transcriptase and integrase enzymes critical to HIV replication, providing protection when taken consistently before potential exposure.","oneSentence":"A program providing multiple antiretroviral formulations for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in at-risk individuals.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:10.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV pre-exposure prophylaxis (PrEP) in at-risk individuals without HIV infection"}]},"trialDetails":[{"nctId":"NCT03981445","phase":"NA","title":"Integrated HIV Prevention and HCV Care for PWID","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2019-11-14","conditions":"HIV Prevention, HCV, Opioid Use","enrollment":446},{"nctId":"NCT07076043","phase":"PHASE4","title":"Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-06-03","conditions":"Hiv","enrollment":1400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Multiple Product PrEP Program","genericName":"Multiple Product PrEP Program","companyName":"University of Alabama at Birmingham","companyId":"university-of-alabama-at-birmingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A program providing multiple antiretroviral formulations for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in at-risk individuals. Used for HIV pre-exposure prophylaxis (PrEP) in at-risk individuals without HIV infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}